Azitra, Inc. (AZTR)
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Azitra, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 6.06M shares outstanding
USAzitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases.
The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Leadership
Francisco D. Salva
President, Chief Executive Officer & Director
Norman Staskey
Chief Financial Officer & Treasurer
Travis Whitfill
Co-Founder, Chief Operating Officer, Secretary & Director
Employees
13
Country
US
Sector
Healthcare
Website
azitrainc.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Salva Francisco D. | President and CEO | Conversion of Derivative | 4.06M | -- | Jun 16, 2026 |
| Salva Francisco D. | President and CEO | Conversion of Derivative | 500 | -- | Jun 16, 2026 |
| Salva Francisco D. | President and CEO | Grant/Award | 220.9K | -- | Apr 20, 2026 |
 Whitfill Travis | Chief Operating Officer | Grant/Award | 64.3K | -- | Apr 20, 2026 |
 Staskey Norm | Chief Financial Officer | Grant/Award | 35.5K | -- | Apr 20, 2026 |
| Salva Francisco D. | President and CEO | Purchase | 4.06M | -- | Mar 18, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Dauntless Investment Group, LLC | 1.1M | 18.6% | 13F |
Stonepine Capital Management, LLC | 528.5K | 8.7% | 13F |
 Salva Francisco D. President and CEO, Director | 408.6K | 6.7% | FORM 4 |
Nantahala Capital Management, LLC | 221.4K | 3.7% | 13F |
Alumni Capital LP · may incl. warrants· filed Dec 2025 | 113.3K | 1.9% | 13G |
L1 Capital Global Opportunities Master Fund, Ltd. · filed Nov 2025 | 0+27.4K via warrants | 0.5% | 13G |
Ayrton Capital LLC · filed May 2025 | 0+25.0K via warrants | 0.4% | 13G |
JANE STREET GROUP, LLC | 24.8K | 0.4% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 9.5K | 0.2% | 13F |
CITADEL ADVISORS LLC | 8.6K | 0.1% | 13F |
Insiders
- Salva Francisco D.President and CEO
- Whitfill TravisChief Operating Officer
- Staskey NormChief Financial Officer
- Ryan BarbaraDirector
- Schroer John R.Director
based on 6.06M shares outstanding
US30d Avg
11.43M
60d Avg
4.54M
90d Avg
2.85M